MegaPro Biomedical Co., Ltd.
🇹🇼Taiwan
Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaLymph Node Metastasis
- Interventions
- Drug: MPB-2043 of 2.0 mg/kgDrug: MPB-2043 of 0.5 mg/kgDrug: MPB-2043 of 3.0 mg/kgDrug: MPB-2043 of 1.0 mg/kg
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06540443
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04643418
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia
Phase 2
Terminated
- Conditions
- Iron Deficiency Anemia
- Interventions
- Drug: IOP Injection / MPB-1514
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT03485053
- Locations
- 🇺🇸
South Florida Research Institute, Lauderdale Lakes, Florida, United States
🇺🇸Whittier Internal Medicine and Nephrology Medical Group, Whittier, California, United States
🇺🇸North America Research Institute, Azusa, California, United States
The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Drug: IOP Injection (MPB-1523)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT03407495
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects
Phase 1
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Drug: IOP Injection
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03399214
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei county, Taiwan
Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects
Phase 1
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Drug: 0.9% normal salineDrug: IOP Injection
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02744248
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
© Copyright 2025. All Rights Reserved by MedPath